Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

被引：0
|
作者：
Grohe, C. [1 ]
Herbst, R. S. [2 ,3 ]
Tsuboi, M. [4 ]
John, T. [5 ]
Majem, M. [6 ]
Goldman, J. W. [7 ]
Kim, S. -W. [8 ]
Marmol, D. [9 ]
Rukazenkov, Y. [10 ]
Wu, Y. -L. [11 ]
Engel-Riedel, W. [12 ]
机构：
[1] Evangel Lungenklin Berlin Buch, Klin Pneumol, Berlin, Germany
[2] Yale Sch Med, Med Oncol, New Haven, CT USA
[3] Yale Canc Ctr, New Haven, CT USA
[4] Natl Canc Ctr Hosp East, Dept Thorac Surg & Oncol, Chiba, Japan
[5] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[8] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] AstraZeneca, Late Oncol Stat, Cambridge, England
[10] AstraZeneca, Oncol Res & Dev, Cambridge, England
[11] South China Univ Technol, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Med, Guangzhou, Peoples R China
[12] Klinikum Stadt Koln gGmbH, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [1] Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA
    John, Thomas
    Herbst, Roy
    Tsuboi, Masahiro
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Marmol, Dominika
    Rukazenkov, Yuri
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 69 - 70
  • [2] Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis
    Jie, W.
    Wu, Y-L.
    Lu, S.
    Wang, Q.
    Li, S.
    Zhong, W.
    Wang, Q.
    Li, W.
    Wang, B.
    Chen, J.
    Cheng, Y.
    Duan, H.
    Li, G.
    Shan, L.
    Liu, Y.
    Huang, X.
    Atasoy, A.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [3] Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Tsuboi, Masahiro
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan Wade
    Kim, Sang-We
    Marmol, Dominika
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
  • [4] Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
    Wang, Jie
    Wu, Yi-Long
    Lu, Shun
    Wang, Qun
    Li, Shanqing
    Zhong, Wen-Zhao
    Wang, Qiming
    Li, Wei
    Wang, Buhai
    Chen, Jun
    Cheng, Ying
    Duan, Hongbing
    Li, Gaofeng
    Shan, Li
    Liu, Yangbo
    Liu, Jing
    Huang, Xiangning
    Bolanos, Ana
    He, Jie
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [5] Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA
    Grohe, C.
    Tsuboi, M.
    Wu, Y.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J.
    Kim, S.
    Yu, C.
    Vu, H.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F.
    Urban, D.
    Stachowiak, M.
    Balanos, A.
    Huang, X.
    Herbst, R.
    Kern, J.
    PNEUMOLOGIE, 2023, 77 : S17 - S17
  • [6] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [7] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [8] SOCIETAL ECONOMIC IMPACT OF TREATMENT WITH ADJUVANT OSIMERTINIB IN PATIENTS WITH EARLY-STAGE (IB-IIIA) EGFRm NSCLC
    Bracke, B.
    Flint, I
    McCrea, C.
    Freigofaite, D.
    Hu, Y.
    Verhoek, A.
    VALUE IN HEALTH, 2023, 26 (06) : S107 - S107
  • [9] EGFR mutation (EGFRm) prevalence and mortality in patients with stage IB-IIIA NSCLC: A cohort study in Denmark
    Jakobsen, E.
    Taylor, A.
    Ehrenstein, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S730 - S731
  • [10] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
12345